New Delhi, May 28: Stock markets will remain closed today, May 28, 2036 on account of Bakri Id, with trading suspended across major segments on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
NEW YORK, May 28 (Reuters) – Oil prices jumped about 2% in early Thursday trading after Reuters reported fresh U.S. strikes overnight on an Iranian military site, escalating tensions even as Washington and Tehran negotiate to end their three-month conflict. Brent crude futures rose $1.90, or 2.02%, to $96.19 a barrel by 0015 GMT, while the more active August contract gained $1.64 or 1.78%, to $93.89. The July contract is set to expire on Friday. The U.S. West Texas Intermediate futures were up $1.73, or 1.95%, at $90.41. Both benchmarks slipped more than 5% to touch their lowest in a
WASHINGTON, May 28, 2026 (AP) — U.S. forces carried out new defensive strikes on Iran on Wednesday after President Donald Trump asserted that Iran is “negotiating on fumes” and insisted that November’s midterm elections in the United States won’t make him rush into a deal to end the nearly three-month-old conflict. U.S. Central Command forces shot down four Iranian one-way attack drones that posed a threat around the Strait of Hormuz, according to U.S. officials who were not authorized to comment publicly and spoke on the condition of anonymity. The U.S. military also struck an Iranian ground control station in
New Delhi, May 27 (PTI) A one-time gene therapy for treating hypercholesterolaemia could lower up to 62 per cent ‘bad’ cholesterol in the blood, with reductions sustaining over time, according to results of Phase 1b clinical trial published in The New England Journal of Medicine. Developed by the US-based pharmaceutical and biotechnology giant Eli Lilly and Company, VERVE-102 is an experimental gene therapy that works by durably turning off the ‘PCSK9’ gene in the liver and lower blood levels of low-density lipoprotein cholesterol (LDL-C) following a single infusion, it said in a statement. The interim analysis of the ‘Heart-2’ trial
